Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (BMY)
NYSE:BMY
BMY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$39.35 - $61.10
Previous CloseN/A
Volume3.98M
Average Volume (3M)11.04M
Market Cap
$110.46B
Enterprise Value$155.61B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Apr 24, 2025EPS Estimate
1.53Last Dividend Ex-Date
Jan 03, 2025Dividend Yield4.4%
Share Statistics
EPS (TTM)-4.43
Shares Outstanding2,029,312,000
10 Day Avg. Volume12,949,311
30 Day Avg. Volume11,040,260
Standard Deviation0.06
R-Squared0.14
Alpha-0.00148
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.29
Price to Cash Flow (P/CF)6.20
P/FCF Ratio6.80
Enterprise Value/Market Cap1.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.28
Enterprise Value/Ebitda49.31
Forecast
1Y Price Target
$60.54Price Target Upside8.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsSeveral clinical catalysts, such as ARISE and ADEPT-2 readouts for Cobenfy, and the ODYSSEY readout for Camzyos, are anticipated to impact the company positively.
Growth PotentialMomentum is building for the company's growth business with a strong launch from Cobenfy and outperformance from Camzyos, Reblozyl, and Breyanzi.
Bears Say
Legacy Business ChallengesThere are challenges for Bristol's legacy business, including the continued erosion of Revlimid and impacts from Part D reform.
---
Ownership Overview
0.07% Insiders
21.76% Mutual Funds
16.11% Other Institutional Investors
38.58% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was $39.35 and its highest was $61.10 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is $110.46B.
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Apr 24, 2025 which is in 62 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Feb 06, 2025. The company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.463 by $0.207.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of $0.62 which represents an annual dividend yield of 4.4%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is 1.53.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,029,312,000 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of $1.67 in its last earnings report, beating expectations of $1.463. Following the earnings report the stock price went down -3.835%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Currently, no hedge funds are holding shares in BMY
---
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$60.54 (8.51% Upside)
$60.54 (8.51% Upside)
Blogger Sentiment
Bullish
BMY Sentiment 95%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 898.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $100.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.78%
12-Months-Change
Fundamentals
Return on Equity
-54.78%
Trailing 12-Months
Asset Growth
-2.69%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
---
BMY Company Deck
---
BMY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive sentiment with strong growth in the company's key growth portfolio and significant achievements in commercial and R&D milestones. However, challenges remain in the legacy portfolio and impacts from Medicare Part D redesign. The company's strategic focus on operational excellence and financial discipline, along with accelerated R&D productivity, supports a positive outlook.Read More>---
BMY Revenue Breakdown
70.61% U.S.
27.33% International
2.06% Other
---
BMY Stock 12 Month Forecast
Average Price Target
$60.54
▲(8.51% Upside)
Technical Analysis
Best Analysts Covering BMY
1 Year
1 Year Success Rate
14/21 ratings generated profit
1 Year Average Return
+3.97%
reiterated a sell rating 25 days ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +3.97% per trade.
---